Sector Expert: Joseph Wagner

BriaCell Therapeutics Corp.

Image: Joseph Wagner

Joseph Wagner, Ph.D., President and CEO of BriaCell, has 15 years' experience in C-level positions in multiple biotech companies. He is the former and president and CEO of OncoCyte Corp., where he led development of three cancer diagnostic products that currently are in trials involving more than 2,000 patients. As president and CTO of Cell Targeting Inc., he was instrumental in its acquisition by BioTime Inc. He led the first allogeneic cell therapy program for heart disease as vice president of Neuronyx, in partnership with Johnson & Johnson. Throughout his career, he has raised more than $100M in capital in public, private and angel funding rounds, and more than $20M in nondilutive grant and collaborative funding.

Recent Interviews

Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level (9/30/15)

Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility.

Due to permission requirements, not all quotes are shown.